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Efficacy of Psychotherapies for Borderline Personality Disorder
A Systematic Review and Meta-analysis
Ioana A. Cristea, PhD; Claudio Gentili, MD, PhD; Carmen D. Cotet, PhD; Daniela Palomba, MD; Corrado Barbui, MD; Pim Cuijpers, PhD
IMPORTANCE Borderline personality disorder (BPD) is a debilitating condition, but several
psychotherapies are considered effective.
OBJECTIVE To conduct an updated systematic review and meta-analysis of randomized
clinical trials to assess the efficacy of psychotherapies for BPD populations.
DATA SOURCES Search terms were combined for borderline personality and randomized trials
in PubMed, PsycINFO, EMBASE, and the Cochrane Central Register of Controlled Trials (from
database inception to November 2015), as well as the reference lists of earlier meta-analyses.
STUDY SELECTION Included were randomized clinical trials of adults with diagnosed BPD
randomized to psychotherapy exclusively or to a control intervention. Study selection
differentiated stand-alone designs (in which an independent psychotherapy was compared
with control interventions) from add-on designs (in which an experimental intervention
added to usual treatment was compared with usual treatment alone).
DATA EXTRACTION AND SYNTHESIS Data extraction coded characteristics of trials, participants,
and interventions and assessed risk of bias using 4 domains of the Cochrane Collaboration
Risk of Bias tool (independent extraction by 2 assessors). Outcomes were pooled using a
random-effects model. Subgroup and meta-regression analyses were conducted.
MAIN OUTCOMES AND MEASURES Standardized mean differences (Hedges g) were calculated
using all outcomes reported in the trials for borderline symptoms, self-harm, suicide, health
service use, and general psychopathology at posttest and follow-up. Differential treatment
retention at posttest was analyzed, reporting odds ratios.
RESULTS Thirty-three trials (2256 participants) were included. For borderline-relevant
outcomes combined (symptoms, self-harm, and suicide) at posttest, the investigated
psychotherapies were moderately more effective than control interventions in stand-alone
designs (g = 0.32; 95% CI, 0.14-0.51) and add-on designs (g = 0.40; 95% CI, 0.15-0.65).
Results were similar for other outcomes, including stand-alone designs: self-harm (g = 0.32;
95% CI, 0.09-0.54), suicide (g = 0.44; 95% CI, 0.15-0.74), health service use (g = 0.40;
95% CI, 0.22-0.58), and general psychopathology (g=0.32; 95% CI, 0.09-0.55), with no
differences between design types. There were no significant differences in the odds ratios
for treatment retention (1.32; 95% CI, 0.87-2.00 for stand-alone designs and 1.01; 95% CI,
0.55-1.87 for add-on designs). Thirteen trials reported borderline-relevant outcomes at
follow-up (g = 0.45; 95% CI, 0.15-0.75). Dialectical behavior therapy (g=0.34; 95% CI,
0.15-0.53) and psychodynamic approaches (g=0.41; 95% CI, 0.12-0.69) were the only types
of psychotherapies more effective than control interventions. Risk of bias was a significant
moderator in subgroup and meta-regression analyses (slope β = −0.16; 95% CI, −0.29 to
−0.03; P = .02). Publication bias was persistent, particularly for follow-up.
CONCLUSIONS AND RELEVANCE Psychotherapies, most notably dialectical behavior therapy
and psychodynamic approaches, are effective for borderline symptoms and related
problems. Nonetheless, effects are small, inflated by risk of bias and publication bias, and
particularly unstable at follow-up.
JAMA Psychiatry. doi:10.1001/jamapsychiatry.2016.4287
Published online March 1, 2017.
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B orderline personality disorder (BPD) is a debilitatingmental disorder characterized by severe instability inaffect, identity, interpersonal relationships, and behav-
ioral dysregulation.1 Alongside a vast array of comorbidities,
parasuicide (ie, nonlethal intentional self-harming behav-
iors) and suicide are commonly associated problems. More than
75% of patients with BPD are believed to engage in deliberate
self-harm.2 Suicide rates are estimated to be between 8% and
10%,3,4 almost 50 times higher than in the general population.5
Borderline personality disorder is the most common person-
ality disorder in clinical populations,5,6 associated with inten-
sive use of mental health services7,8 even in the absence of a
full diagnosis.9 Functional impairment is considerable com-
pared with other personality disorders10 and is enduring in the
absence of a change in personality psychopathology.11
Several psychotherapy approaches were specifically de-
veloped for the disorder, most notably dialectical behavior
therapy (DBT),12 cognitive behavior therapy (CBT),13 and psy-
chodynamic treatments, such as mentalization-based therapy14
or transference-focused psychotherapy.15 Each approach ap-
peared to be more effective than treatment as usual (TAU) for
BPD-related problems, such as suicidality or parasuicidal
behavior.16-19 Trials of direct comparisons of treatments for BPD
reported few differences among them.20,21 However, most trials
demonstrating effectiveness were conducted with the direct
participation of the treatment developer. Previous meta-
analyses of psychotherapeutic treatments for BPD have been
scarce and used focused criteria for assessing effectiveness,
avoiding combining treatments. One meta-analysis22 of DBT
for BPD reported moderate effects for borderline-relevant out-
comes, suicidality, and self-harm. However, analysis re-
stricted to randomized clinical trials (RCTs) showed reduced
effects, with nonsignificance for suicidality and self-harm. An-
other meta-analysis23 of RCTs for BPD reported only moder-
ate effects for the comparison between DBT and TAU.
Conversely, because effectiveness differences between
therapies appear to be limited and because variations of the
same intervention are to be expected in diverse implementa-
tion settings, we believe that a broader effectiveness evalua-
tion grouping therapies into theoretically intelligible catego-
ries is germane. Heterogeneity, publication bias, and potential
moderators of efficacy (eg, treatment duration and type of psy-
chotherapy) are additional unclear issues. Moreover, because
the study collection dates of the 2 previous meta-analyses22,23
preceded 2012, new trials or follow-ups of older trials pub-
lished since then should be considered. Therefore, our objec-
tive was to conduct an updated systematic review and meta-
analysis of RCTs to assess the efficacy of psychotherapies
for BPD-relevant outcomes at posttest and, where possible, at
follow-up.
Methods
Identification and Selection of Studies
Studies were identified through searches in 4 bibliographical
databases (from database inception to November 2015 in
PubMed, PsycINFO, EMBASE, and the Cochrane Central Reg-
ister of Controlled Trials) using the search term borderline
personality (both text word and Medical Subject Headings
term), with a filter for randomized trials (eMethods in the
Supplement). We also checked the reference lists of earlier
meta-analyses.22,23
Studies were included if they were RCTs in which a psy-
chotherapy was compared with a control condition for adults
diagnosed as having BPD. Given the diversity and complexity
of therapy orientations, we used an inclusive approach in de-
lineating the psychotherapy and control conditions. We used
a customary definition of psychotherapy emphasizing verbal
communication, structured and purposeful therapist-
patient encounters, and the establishment of a therapeutic
relationship.24,25 No constraints were placed on the control
group, which could include (but was not restricted to) TAU or
other treatments not specifically developed for BPD. Compari-
sons between 2 different psychotherapies specifically devel-
oped for BPD (ie, DBT and transference-focused psycho-
therapy) or between forms of the same psychotherapy (eg, DBT
vs its skills training component) were excluded because of ex-
pectations of similar efficacy. Concomitant medication use was
not an exclusion criterion unless it was prescribed in a stan-
dardized way, as in trials in which individuals were random-
ized to a combination of psychotherapy and either pharma-
cotherapy or placebo. Medication use followed a systematic
protocol, and we could not disentangle its effects from those
of psychotherapy. Studies on even partially adolescent samples
were excluded because BPD diagnosis and treatment pose dis-
tinct challenges for this group. No language restrictions were
applied. One researcher (I.A.C.) screened all records, and full
texts were obtained for RCTs. Two independent assessors
(I.A.C. and C.D.C.) examined the full texts and selected eli-
gible RCTs.
Risk of Bias and Data Extraction
Trial risk of bias (RoB) was evaluated within 4 domains of the
Cochrane Collaboration Risk of Bias tool,26 which assesses
sources of bias in RCTs. Rated domains included (1) adequate
Key Points
Question What is the efficacy of psychotherapy for borderline
personality disorder?
Findings In this systematic review and meta-analysis of
randomized clinical trials, outcomes of psychotherapies (most
notably dialectical behavior therapy and psychodynamic
approaches) significantly improved borderline-relevant outcomes
(symptoms, self-harm, and suicide) compared with control
interventions. However, differences dissipated in well-designed
and implemented trials or if the control group was balanced for
manualization of treatment or the involvement of the study team
in treatment.
Meaning Psychotherapies specifically designed for borderline
personality disorder have significant yet modest benefits over
treatment as usual, and future independent and well-conducted
trials are needed to clarify the stability and practical relevance of
their effects.
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generation of allocation sequence, (2) concealment of alloca-
tion to conditions, (3) prevention of knowledge of the allo-
cated intervention to assessors of outcome (masking of asses-
sors), and (4) dealing with incomplete data. This last domain
was assessed as low risk if proper intent-to-treat (ITT) analy-
ses were conducted, meaning that authors used a method for
imputing missing values so that all randomized participants
were included in the analyses. Masking of assessors was rated
as low risk if the trial described proper methods of ensuring
masking or if all relevant outcome measures were self-report
instruments, thus not requiring the direct interaction with an
assessor. For use in meta-regression analyses, we computed
an overall RoB score for each study by awarding 1 point for each
bias source rated as low risk.
Among trials, we distinguished between stand-alone
designs (in which the experimental group received a full
course of an independent BPD psychotherapy and the con-
trol group received TAU or another therapy not specific for
BPD) and add-on designs (in which both groups received
TAU and the experimental group received an additional BPD
therapy). We also extracted characteristics of the partici-
pants, interventions, and studies, including therapy type
(DBT, psychodynamic, CBT, or other); control group (TAU,
supportive therapy, or an ad hoc control, designed as part of
the trial); whether the control group was manualized (ie, fol-
lowed a treatment protocol or manual); involvement or non-
involvement of the study team in treating the control group;
the presence or absence of a treatment developer as an
author of the trial report; therapist supervision for the
experimental group (by the treatment developer or by oth-
ers); and low RoB (studies rated as low risk for ≤2 vs ≥3 RoB
domains). We also extracted the following treatment inten-
sity variables: treatment duration (in months), treatment
exposure (in hours, calculated by multiplying the session
duration for individual or group therapy by the number of
sessions either planned or, if available, attended on average
for the experimental and control groups), and difference in
treatment exposure between the intervention and control
groups (in hours). Risk of bias assessment and data extrac-
tion were performed by 2 independent assessors. Interrater
agreement κ statistics were computed (eMethods in the
Supplement), and disagreement was resolved by discussion
among assessors and with the senior author (P.C.).
Meta-analysis
To capture the breadth and variability of reported outcomes,
we grouped them into the following categories: borderline
relevant (BPD symptom measures, self-harm and parasui-
cide, and suicidal behaviors), borderline symptoms (only
BPD symptom measures), self-harm and parasuicidal behav-
ior, suicidal behavior, health service use (hospitalizations
[whether psychiatric or general], use of emergency services,
use of additional outpatient services, and medication use),
and general psychopathology (general psychopathology,
anxiety, or depression). Treatment retention was computed
as the comparative dropout rates between the intervention
and control groups. Dropouts (eMethods in the Supplement)
were defined as all randomized participants not finishing
treatment, regardless of the reasons. Adverse effects were
defined as participant death by suicide and as death from
any cause after randomization.
The between-group effect size was calculated as the dif-
ference between the intervention and control groups at post-
test and at follow-up (Hedges g), corrected for small sample
sizes.27 Follow-up data more than 2 years from treatment ter-
mination or in which the control group also received the ex-
perimental treatment were not included. Data across mul-
tiple follow-up points were averaged at the study level for each
outcome category. For treatment retention, odds ratios indi-
cated the odds of maintaining participants in treatment in the
intervention group vs the control group.
If a trial reported data on multiple outcomes in the same
category, the mean effect size was calculated using the pro-
cedures by Borenstein et al28 so that each trial reported just
one effect size in a category at each time point. Where avail-
able, the means (SDs) were used, but if only dichotomous out-
comes were reported, we used available procedures28 to com-
pute the standardized mean difference. If a study did not
include sufficient data for effect size calculation, the authors
were contacted, and the study was excluded if they failed to
provide data. Where available, ITT data were preferred. Ef-
fect sizes for dichotomous outcomes were computed, adher-
ing to the ITT principle, by reporting the observed or im-
puted number of patients with an event (eg, self-harm) relative
to the total number of patients randomized to that group.
We used a software program (Comprehensive Meta-
Analysis, version 3; Biostat) for computing and pooling effect
sizes, with a random-effects model for pooling effect sizes. We
calculated the number needed to treat using the formulas by
Kraemer and Kupfer.29 Heterogeneity was assessed with the
I2 statistic: 0% indicates no observed heterogeneity, and higher
values indicate increasing heterogeneity, with 25%, 50%, and
75% defining thresholds for low, moderate, and high. We cal-
culated 95% CIs around I2 statistics30 using a noncentral χ2-
based approach (heterogi module for Stata, version 8; Stata-
Corp LP).31 Outliers were defined as studies in which the 95%
CI was outside the 95% CI of the pooled studies (on both sides).
For categorical moderators, we conducted subgroup analy-
ses using a mixed-effects model.28 For continuous modera-
tors, meta-regression analyses used a restricted maximum like-
lihood model with the Knapp-Hartung method.28 We examined
publication bias through visual funnel plot inspection, the trim-
and-fill procedure32 (which produces an effect size estimate
after accounting for publication bias), and Egger test for fun-
nel plot asymmetry.
Results
Selection and Inclusion of Studies
We screened 1058 abstracts, removed 500 duplicates, and sub-
sequently retrieved 158 full-text articles. Thirty-eight trials ex-
amined a psychotherapy, with 5 excluded for comparing 2 ver-
sions of the same therapy. Consequently, 33 trials (2256
participants) met our inclusion criteria, and 28 of them had
enough data for calculating effect sizes (eFigure 1 in the Supple-
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ment). For the 5 missing trials,20,33-36 the authors were con-
tacted, but they did not provide the requested data.
Characteristics of Included Studies
The 33 trials included 1169 participants in the investigated treat-
ment group and 1087 participants in the control group (eTable
1 in the Supplement). Seventeen trials targeted patients with
BPD diagnosed using a structured clinical interview, 10 trials
targeted patients with BPD with recent documented self-
harm, and the rest targeted special BPD populations (eg, vet-
erans and individuals with addiction). Twenty-two trials had
a stand-alone design, and 11 trials had an add-on design. Twelve
trials had women-only samples, and this percentage ranged
from 0% to 95% in the remainder. The best-represented ap-
proaches were DBT (12 trials), psychodynamic therapies (8
trials), and CBT (5 trials). Twenty-one trials had TAU as the con-
trol treatment, and the control treatment was manualized in
10 trials. The treatment developer was an author in 20 trials.
In 15 trials, the treatment developer was a therapist or super-
vised therapists directly. Treatment duration ranged from 2.5
to 24 months, and the number of sessions (for individual and
group therapy taken together) ranged from 6 to 312.
The κ statistics indicated high interrater agreement for RoB
estimations (eMethods in the Supplement), which were vari-
able (eFigure 2 in the Supplement). Sixteen trials reported ad-
equate sequence generation, 12 trials properly concealed al-
location, and 20 trials implemented masking of outcome
assessors (2 used self-report measures only). However, for in-
complete outcome data, only 13 trials were rated as low RoB,
and more than half had high RoB. Eleven trials could be rated
as low risk on 3 or 4 domains.
Main Effects at Posttest
Stand-alone Designs
Results showed significant effects for all outcome categories,
ranging from 0.31 (0.04-0.57) for borderline symptoms to 0.44
(0.15-0.74) for suicide outcomes (Table 1). Heterogeneity was
moderate to high with the exception of health service use. For
all borderline-relevant outcomes (eFigure 3 in the Supple-
ment), 17 trials had a Hedges g of 0.32 (95% CI, 0.14-0.51), with
moderate heterogeneity (48%).
Add-on Designs
For borderline-relevant outcomes (Table 1 and eFigure 3 in the
Supplement), 10 trials had a Hedges g of 0.40 (95% CI, 0.15-
0.65), with moderate heterogeneity (50%). Results were not
significant for self-harm and parasuicidal behavior or for health
service use, but the number of trials was small (range, 3-6).
All Trials
Combining both design types for all borderline-relevant out-
comes (combining borderline symptoms, self-harm and para-
Table 1. Main Effects at Posttest and Follow-up of Trials Comparing Experimental Psychotherapy and Control Treatments
for Borderline Personality Disorder
Variable




































































































































Abbreviation: NNT, number needed to treat.
a According to the random-effects model. A positive effect indicates superiority
of the experimental psychotherapy over control treatments.
b The P values indicate whether the difference between the effect sizes in the
group of trials with stand-alone vs add-on designs is significant.
c Borderline-relevant outcomes include borderline symptoms, self-harm and
parasuicidal behavior, and suicide.
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suicidal behavior, and suicide) yielded a significant effect
(g = 0.35; 95% CI, 0.20-0.50 [27 trials]), with moderate hetero-
geneity (48%) (Table 2 and Figure). Results with outliers ex-
cluded or excluding comparisons with supportive therapy were
similar.
For treatment retention, results were not significant for
stand-alone designs (odds ratio, 1.32; 95% CI, 0.87-2.00 [15
trials]) or add-on designs (odds ratio, 1.01; 95% CI, 0.55-1.87
[10 trials]), and heterogeneity was moderate to high (59% for
stand-alone designs and 44% for add-on designs). There
were no significant differences between the 2 design types
on any of the symptom outcome categories or on treatment
retention.
Main Effects at Follow-up
Adverse Effects
There were 2 deaths by suicide in the treatment group and
5 deaths by suicide in the control group. The treatment group
and the control group each had 6 all-cause deaths.
Stand-alone Designs
Seven trials had a significant effect of 0.56 (95% CI, 0.17-
0.95) for all borderline-relevant outcomes (Table 1). Hetero-
geneity was high (62%). The number of trials was too small
(range, 3-5) for the other outcome categories.
Add-on Designs
Six trials had a nonsignificant effect (g = 0.35; 95% CI, −0.15
to 0.85) for all borderline-relevant outcomes (Table 1). Hetero-
geneity was high (79%). There were too few trials (range, 2-5)
in the other outcome categories.
All Trials
Combining both design types yielded a significant effect
(g = 0.45; 95% CI, 0.15-0.75 [13 trials]), with high heteroge-
neity (70%). These results are summarized in Table 2 and in
eFigure 4 in the Supplement.
Subgroup and Meta-regression Analyses
Subgroup Analyses
These analyses were conducted on the most inclusive out-
come category (all borderline-relevant outcomes), combin-
ing stand-alone and add-on designs because we found no
differences among them (Table 2 and eTable 2 in the
Supplement). The DBT (g=0.34; 95% CI, 0.15-0.53 [9 trials])
and psychodynamic approaches (g=0.41; 95% CI, 0.12-0.69
[7 trials]) were more effective than control interventions,
while CBT (g = 0.24; 95% CI, −0.01 to 0.49 [5 trials]) and
other interventions (g = 0.38; 95% CI, −0.15 to 0.92 [6
trials]) were not.
Trials with an ad hoc control group developed as part of
the study, trials in which the control intervention was manu-
alized, or trials in which the study team was involved in treat-
ing the control group, as well trials with low RoB for 3 or 4 do-
mains, generated nonsignificant between-group effects.
Psychotherapies were more effective than control interven-
tions in trials with more RoB than in those with less RoB (0.48
vs 0.11, P = .01).
Meta-regression Analyses
Risk of bias (the number of criteria with low RoB) had a sig-
nificant negative association with outcomes at posttest (slope
β = −0.16; 95% CI, −0.29 to −0.03; P = .02) (eFigure 5 in the
Supplement). Dropout rates in the treatment group, treat-
ment duration, treatment exposure in the treatment group or
the control group, and difference in treatment exposure be-
tween groups were not significantly related to outcomes.
Publication Bias
Inspection of the funnel plot and the trim-and-fill procedure
documented publication bias for borderline-relevant out-
comes (eFigure 6 in the Supplement). At posttest, consider-
ing all trials, adjustment for missing studies (n = 6) decreased
the effect size from a Hedges g of 0.35 (95% CI, 0.20-0.50) to
0.23 (95% CI, 0.07-0.38). For stand-alone designs, 4 studies
were imputed, leading to a smaller but significant Hedges g of
0.20 (95% CI, 0.01-0.39). For add-on designs, 2 studies were
imputed, resulting in a Hedges g of 0.30 (95% CI, 0.05-0.56).
Egger test was not significant in any of these cases. At follow-
up, considering all trials, adjustment for missing studies (n = 3)
led to a nonsignificant Hedges g of 0.19 (95% CI, −0.15 to 0.53),
and Egger test was significant (intercept β = 2.78; 95% CI, 0.18-
5.39; P = .04).
Discussion
We conducted an updated systematic review and meta-
analysis of RCTs of psychotherapies for BPD. We included 33
trials, either stand-alone designs (an independent experi-
mental treatment vs TAU or another control) or add-on
designs (an experimental treatment superimposed to TAU vs
TAU alone). We examined disorder-specific outcomes (BPD
symptoms, self-harm and parasuicide, and suicide) and
more general outcomes, such as psychopathology or health
service use. Most trials (22 of 33) had stand-alone designs,
and our results showed significant, small, posttest between-
group effect sizes, with high to moderate heterogeneity
across all outcome categories. Results were more variable for
add-on designs, including nonsignificant effects. Nonethe-
less, the number of trials for some outcome categories was
small, and these findings should be viewed as tentative and
possibly spurious. However, for borderline-relevant out-
comes and psychopathology (for which most add-on trials
included measures), effects were small to medium. We oper-
ated with this design distinction so as not to confound
more intensive psychotherapeutic treatments with others
designed to complement usual treatment, although subse-
quent subgroup analysis found no difference between the 2
design types on any of the outcome categories. We also
found no differences between types of psychotherapies.
Most trials focused on DBT followed by psychodynamic
approaches, and both types generated significant, small
between-group effect sizes, with low heterogeneity for DBT.
Surprisingly, CBT was not superior to control conditions.
Although this result was based on only 5 trials, heteroge-
neity was low.
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Table 2. Main Effects and Results of Subgroup and Meta-regression Analyses at Posttest and Follow-up
of Trials, Combining Both Design Types, for Borderline-Relevant Outcomes
Variable
No. of
Trials Hedges g (95% CI)a I2 (95% CI), % NNT P Valueb
Posttest
Borderline-relevant outcomesc 27 0.35 (0.20 to 0.50) 48 (9 to 66) 5.10 NA
Outliers excluded 26 0.38 (0.25 to 0.51) 33 (0 to 57) 4.72 NA
Comparisons with supportive
therapy excluded
24 0.35 (0.19 to 0.50) 48 (5 to 67) 5.10 NA
Outcomes measured on scales
created by the treatment
developer
15 0.26 (0.10 to 0.41) 27 (0 to 60) 6.85 NA
Studies conducted by and
outcomes measured on scales
created by the treatment
developer
9 0.36 (0.12 to 0.60) 44 (0 to 72) 5.00 NA
Subgroup analysisd
Dialectical behavior therapy 9 0.34 (0.15 to 0.53) 19 (0 to 62) 5.26
.87
Psychodynamic approaches 7 0.41 (0.12 to 0.69) 42 (0 to 74) 4.39
Cognitive behavior therapy 5 0.24 (−0.01 to 0.49) 15 (0 to 69) 7.46
Other interventions 6 0.38 (−0.15 to 0.92) 79 (41 to 89) 4.72
Control group
Treatment as usual 18 0.40 (0.25 to 0.56) 22 (0 to 57) 4.50
.49Supportive therapy 3 0.37 (−0.36 to 1.09) 62 (0 to 87) 4.85
Ad hoc control group 6 0.17 (−0.17 to 0.52) 73 (13 to 86) 10.42
Control group manualized
No 19 0.39 (0.25 to 0.53) 17 (0 to 52) 4.59
.27
Yes 7 0.16 (−0.22 to 0.55) 73 (26 to 86) 11.11
Study team treating the control
group
No 17 0.42 (0.28 to 0.56) 6 (0 to 48) 4.27
.14
Yes 10 0.18 (−0.11 to 0.46) 67 (21 to 81) 9.80
Treatment developer a trial
author
No 12 0.31 (0.16 to 0.46) 5 (0 to 52) 5.75
.79
Yes 15 0.35 (0.10 to 0.59) 63 (26 to 78) 5.10
Therapist supervision
Treatment developer 11 0.37 (0.13 to 0.62) 52 (0 to 74) 4.85
.49
Other 8 0.26 (0.08 to 0.45) 9 (0 to 60) 6.85
Low risk of bias criteria
0-2 18 0.48 (0.33 to 0.64) 15 (0 to 52) 3.76
.01
3-4 9 0.11 (−0.12 to 0.35) 57 (0 to 78) 16.13
Follow-up
Borderline-relevant outcomesc 13 0.45 (0.15 to 0.75) 70 (41 to 82) 4.00 NA
Outliers excluded 12 0.32 (0.08 to 0.55) 52 (0 to 73) 5.56 NA
Comparisons with supportive
therapy excluded
12 0.47 (0.16 to 0.78) 73 (45 to 83) 3.85 NA
Subgroup analysisd
Dialectical behavior therapy 4 0.42 (−0.02 to 0.87) 62 (0 to 85) 4.27
.18
Psychodynamic approaches 2 0.40 (−1.10 to 1.89) 88 (Not
available)e
4.50
Cognitive behavior therapy 5 0.12 (−0.12 to 0.35) 0 (0 to 64) 14.71




Treatment as usual 9 0.52 (0.10 to 0.94) 76 (48 to 86) 3.50
.63
Ad hoc control group 3 0.36 (−0.11 to 0.84) 66 (0 to 88) 5.00
(continued)
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Follow-up results for all borderline-relevant outcomes
showed significant medium effects for stand-alone designs and
nonsignificant results for add-on designs. Heterogeneity was
high, reflecting substantial differences in follow-up duration
and type among trials, with some being naturalistic and oth-
ers including booster interventions, which in some cases were
intensive.37 We did not include follow-up points more than 2
years after treatment termination because a longer time span
Figure. Borderline-Relevant Outcomes
–2.0 1.0 2.00





PsychotherapySource Hedges g (95% CI)
Amianto et al,43 2011 –0.34 (–1.01 to 0.34)
Bateman and Fonagy,37 1999 1.06 (0.28 to 1.83)
Bateman and Fonagy,16 2009 0.75 (0.28 to 1.23)
Blum et al,44 2008 0.31 (–0.04 to 0.66)
Bos et al,41 2010 0.22 (–0.30 to 0.74)
Carter et al,45 2010 0.10 (–0.45 to 0.66)
Cottraux et al,46 2009 –0.48 (–1.53 to 0.56)
Davidson et al,17 2006 0.10 (–0.30 to 0.51)
Doering et al,18 2010 0.25 (–0.13 to 0.64)
Farrell et al,47 2009 1.04 (0.25 to 1.84)
Gratz and Gunderson,48 2006 1.02 (0.16 to 1.88)
Gratz et al,49 2014 0.89 (0.35 to 1.43)
Gregory et al,50 2008 0.26 (–0.51 to 1.03)
Jørgensen et al,51 2013 0.35 (–0.15 to 0.85)
Koons et al,42 2001 0.62 (–0.25 to 1.50)
Kramer et al,52 2014 0.07 (–0.38 to 0.52)
Leppänen et al,53 2016 0.25 (–0.31 to 0.81)
Linehan et al,38 1991 0.49 (–0.14 to 1.11)
Linehan et al,19 2006 0.30 (–0.12 to 0.72)
McMain et al,40 2009 0.02 (–0.27 to 0.31)
Pascual et al,54 2015 –0.73 (–1.32 to –0.14)
Priebe et al,55 2012 0.42 (–0.05 to 0.89)
Reneses et al,56 2013 0.55 (–0.05 to 1.16)
Soler et al,57 2009 0.56 (0.04 to 1.08)
Turner,58 2000 1.07 (0.24 to 1.91)
Verheul et al,39 2003 0.51 (–0.14 to 1.16)
Weinberg et al,59 2006 0.82 (0.06 to 1.57)
Overall 0.35 (0.20 to 0.50)
Shown are standardized posttest




(borderline symptoms, self-harm and
parasuicidal behavior, and suicide) for
27 trials.16-19,37-59
Table 2. Main Effects and Results of Subgroup and Meta-regression Analyses at Posttest and Follow-up
of Trials, Combining Both Design Types, for Borderline-Relevant Outcomes (continued)
Variable
No. of
Trials Hedges g (95% CI)a I2 (95% CI), % NNT P Valueb
Control group manualized
No 10 0.50 (0.13 to 0.87) 73 (42 to 84) 3.62
.61
Yes 3 0.31 (−0.31 to 0.93) 64 (0 to 88) 5.75
Study team treating the control
group
No 8 0.63 (0.19 to 1.07) 76 (43 to 87) 2.91
.15
Yes 5 0.20 (−0.19 to 0.58) 52 (0 to 81) 8.93
Treatment developer a trial
author
No 4 0.14 (−0.09 to 0.37) 0 (0 to 68) 12.82
.09
Yes 9 0.57 (0.12 to 1.02) 77 (51 to 87) 3.18
Therapist supervision
Treatment developer 7 0.32 (−0.07 to 0.73) 63 (0 to 82) 5.56
.49
Other 4 0.62 (−0.11 to 1.36) 85 (54 to 93) 2.96
Low risk of bias criteria
0-2 9 0.56 (0.13 to 0.99) 75 (45 to 86) 3.25
.24
3-4 4 0.23 (−0.12 to 0.57) 46 (0 to 81) 7.69
Abbreviations: NNT, number needed
to treat; NA, not applicable.
a According to the random-effects
model.
b The P values indicate whether the
difference between the effect sizes
in the subgroups is significant.
c Borderline-relevant outcomes
include borderline symptoms,
self-harm and parasuicidal behavior,
and suicide.
d Subgroup analyses were conducted
using a mixed-effects model. Only
subgroups with at least 2 trials were
included.
e The 95% CIs around I2 cannot be
calculated if there are fewer than
3 subgroups.
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increases the risk of biasing effects from factors extraneous to
the intervention. Adverse effects were rare in both the experi-
mental and control treatment groups.
A surprising finding regarded treatment retention, for
which we found no significant differences between the ex-
perimental treatment and control groups. This result re-
mained stable for both design types and showed moderate
heterogeneity. Improving treatment retention has generally
been seen as a substantial advantage of psychotherapies for
BPD, and most trials in general have demonstrated very favor-
able evaluations. This discrepancy might stem from the fact
that individual trials used variable ways of calculating drop-
out rates, while we used a standard ITT method whereby all
participants who did not finish treatment after randomiza-
tion were considered dropouts regardless of whether they
started treatment or what their specific reasons were for dis-
continuing it. Moreover, in calculating rates, we reported the
absolute number of dropouts relative to the number of ran-
domized participants in each group. In contrast, individual
trials used very diverse methods for defining dropouts, such
as considering participants who switched therapists19,38,39 or
who missed 4 consecutive sessions.40 In other cases, partici-
pants who did not initiate treatment were not counted when
calculating dropout rates.39,41,42 One meta-analysis60 of treat-
ment completion in BPD reported high treatment completion
rates (approximately 75%) but with substantial between-
study heterogeneity. However, included studies were both ob-
servational and controlled trials, randomized or not. Unlike
herein, the authors did not calculate differences in treatment
completion between the experimental and control groups. In-
stead, they pooled absolute rates for the former, a procedure
that is discouraged because it can lead to extremely high lev-
els of heterogeneity.61
We further investigated the potential sources of hetero-
geneity in subgroup and meta-regression analyses. More than
half of the trials included the treatment developer as an au-
thor, but they generated similar effects as independent trials.
Yet a subtler effect potentially related to the involvement of
the treatment developer emerged: differences between the ex-
perimental treatment and control groups were no longer sig-
nificant in trials with an ad hoc control group developed as part
of the study, where the control intervention was manualized,
or where the study team was involved in treating the control
group. We can speculate that, at least in part, the differential
efficacy of psychotherapies designed for BPD in contrast to
usual treatment could be due to the “special attention” granted
to the experimental group or indeed to having a manualized,
structured treatment. Nevertheless, treatment intensity (both
treatment duration and exposure) was not related to the treat-
ment outcomes considered.
Trial RoB consistently emerged as a moderator of effect
sizes in both subgroup and meta-regression analyses. Trials
with low RoB for at least 3 of the 4 domains considered gen-
erated nonsignificant effects for borderline-relevant out-
comes. Moreover, there was a linear relationship between the
number of criteria with low RoB and effect sizes: effects de-
creased by 0.16 for each additional domain that could be rated
as low RoB. There was also evidence of publication bias for
posttest results and particularly for follow-up. Its potential
adjustment reduced effect sizes to smaller, albeit significant,
values for both design types at posttest but to nonsignificant
values for both design types at follow-up.
Limitations
Our meta-analysis has several limitations. Some outcome cat-
egories or subgroups included data from a small number of
trials, rendering resultant effect sizes potentially uncertain. For
5 trials, we did not obtain access to data necessary for calcu-
lating effect sizes. Furthermore, most trials had not been reg-
istered in clinical trial registries, so we could not rate RoB be-
cause of selective outcome reporting. Our search was broad,
but we may have missed trials that addressed personality dis-
orders in general but ultimately had a sample composed of pa-
tients with BPD. Owing to the small number of trials, we
grouped therapies in broader categories, effacing subtler dif-
ferences between orientations. Frequently cited approaches,
such as schema-focused therapy, were underrepresented,
mainly because they were mostly studied in head-to-head
trials. The use of adjunct medication was neither standard-
ized nor consistently reported and could have confounded psy-
chotherapy effects.
Conclusions
Various independent psychotherapies demonstrated efficacy
for borderline-relevant symptoms, self-harm, suicide, health
service use, and general psychopathology in BPD. However,
effects were small, inflated by publication bias, and particu-
larly unstable for follow-up. These effects were no longer sus-
tained in trials with low RoB. While treatment intensity per
se did not seem to influence outcomes, there are indications
that a control group balanced for the involvement of the
study team in treatment or with a manualized protocol is as
effective as psychotherapies tailored for BPD. We found no
evidence that treatment retention would be higher for spe-
cific psychotherapies than for control interventions, contra-
dicting systematic claims from individual trials. Future trials
should implement prospective registration in clinical trial
registries.
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